Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.
PURPOSE: Patients with cancer are at increased risk of severe COVID-19 disease, but have heterogeneous presentations and outcomes. Decision-making tools for hospital admission, severity prediction, and increased monitoring for early intervention are critical. We sought to identify features of COVID-19 disease in patients with cancer predicting severe disease and build a decision support online tool, COVID-19 Risk in Oncology Evaluation Tool (CORONET). METHODS: Patients with active cancer (stage I-IV) and laboratory-confirmed COVID-19 disease presenting to hospitals worldwide were included. Discharge (within 24 hours), admission (≥ 24 hours inpatient), oxygen (O2) requirement, and death were combined in a 0-3 point severity scale. Association of features with outcomes were investigated using Lasso regression and Random Forest combined with Shapley Additive Explanations. The CORONET model was then examined in the entire cohort to build an online CORONET decision support tool. Admission and severe disease thresholds were established through pragmatically defined cost functions. Finally, the CORONET model was validated on an external cohort. RESULTS: The model development data set comprised 920 patients, with median age 70 (range 5-99) years, 56% males, 44% females, and 81% solid versus 19% hematologic cancers. In derivation, Random Forest demonstrated superior performance over Lasso with lower mean squared error (0.801 v 0.807) and was selected for development. During validation (n = 282 patients), the performance of CORONET varied depending on the country cohort. CORONET cutoffs for admission and mortality of 1.0 and 2.3 were established. The CORONET decision support tool recommended admission for 95% of patients eventually requiring oxygen and 97% of those who died (94% and 98% in validation, respectively). The specificity for mortality prediction was 92% and 83% in derivation and validation, respectively. Shapley Additive Explanations revealed that National Early Warning Score 2, C-reactive protein, and albumin were the most important features contributing to COVID-19 severity prediction in patients with cancer at time of hospital presentation. CONCLUSION: CORONET, a decision support tool validated in health care systems worldwide, can aid admission decisions and predict COVID-19 severity in patients with cancer.
EML4-ALK is an oncogenic fusion protein present in approximately 5% of non–small cell lung cancers (NSCLC). Alternative breakpoints in the gene encoding EML4 result in distinct variants that are linked to markedly different patient outcomes. Patients with EML4-ALK variant 3 (V3) respond poorly to ALK inhibitors and have lower survival rates compared with patients with other common variants, such as V1. Here, we use isogenic Beas-2B bronchial epithelial cell lines expressing EML4-ALK V1 or V3, as well as ALK-positive NSCLC patient cells that express V1 (H3122 cells) or V3 (H2228 cells), to show that EML4-ALK V3 but not V1 leads to hyperstabilized K-fibers in mitosis, as well as errors in chromosome congression and segregation. This is consistent with our observation that EML4-ALK V3 but not V1 localizes to spindle microtubules and that wild-type EML4 is a microtubule stabilizing protein. In addition, cells expressing EML4-ALK V3 exhibit loss of spindle assembly checkpoint control that is at least in part dependent on ALK catalytic activity. Finally, we demonstrate that cells expressing EML4-ALK V3 have increased sensitivity to microtubule poisons that interfere with mitotic spindle assembly, whereas combination treatment with paclitaxel and clinically approved ALK inhibitors leads to a synergistic response in terms of reduced survival of H2228 cells. Implications: This study suggests that combining the microtubule poison, paclitaxel, with targeted ALK inhibitors may provide an effective new treatment option for patients with NSCLC with tumors that express the EML4-ALK V3 oncogenic fusion.
EML4-ALK V3 but not V1 localizes to microtubules during mitosis. A–D, H2228 and H3122 cells were grown on coverslips, stained with α-tubulin (red) and ALK (green) antibodies, and subjected to immunofluorescence microscopy analysis. DNA was stained with Hoechst 33258 (blue). Scale bars in metaphase, 5 μm, and in interphase, 10 μm. Colocalization of EML4-ALK with microtubules in interphase (A and B) and metaphase (C and D) was determined by measuring Pearson correlation coefficient along three 2 µm lines in 10 cells. ****, P < 0.0001 compared with H3122 cells by unpaired T test. E–H, Beas-2B cells expressing either HA-EML4-ALK V3 or V1 were induced for 48 hours and stained with HA (green) and α-tubulin (red) antibodies. DNA was stained with Hoechst 33258 (blue). Colocalization of EML4-ALK with microtubules in interphase (E and F) and metaphase (G and H) was determined by measuring Pearson correlation coefficient along three 2 µm lines in 10 cells. ****, P < 0.0001 and ***, P < 0.001 compared with HA-V1 cells by unpaired T test. Scale bars in metaphase, 5 μm, and in interphase, 10 μm. The three different shapes and colours in the dot plots in B, D, F, and H indicate data from three independent experiments, with large shapes referring to means and small shapes the individual data points. I and J, SRRF image reconstruction of EML4-ALK V3 (green) microtubules (red) in an interphase and metaphase H2228 (I) and Beas-2B:HA-EML4-ALK V3 (J) cell stained as above. Data are means +SD for three independent experiments.
H2228 (V3) cells have increased mitotic errors compared with H3122 (V1) cells. A, C, E and G, H3122 and H2228 cells were stained with α-tubulin (red) and γ-tubulin (green) antibodies. DNA was stained with Hoechst 33258 (blue). Scale bars in metaphase, 5 μm, and in interphase, 10 μm. B, Box plot showing the proportion of cells with multipolar spindles quantified from 100 mitotic cells in A. *, P < 0.05 compared with H3122 by unpaired T test. D, Box plot showing the proportion of cells with misaligned chromosomes quantified from 100 bipolar metaphase cells in C. **, P < 0.01 compared with H3122 by unpaired t test. F, Box plot showing the proportion of cells with lagging chromosomes quantified from 100 anaphase cells in E. *, P < 0.05 compared with H3122 by unpaired t test. H, Box plot showing the proportion of cells with micronuclei quantified from 100 interphase cells in G. *, P < 0.05 compared with H3122 by unpaired t test. Data are means +SD for three independent experiments.